David S. Snyder

David S. Snyder brings to Coya Therapeutics over 25 years of experience as the CFO of public and high-growth companies. Prior to joining Coya, Mr. Snyder served as the CFO of DisperSol Technologies, LLC and its wholly-owned subsidiary Austhera BioSciences, Inc. DisperSol and Austhera are currently advancing two late-stage, small molecule drugs through the clinic and are using their proprietary KinetiSol platform to build a pipeline of NCEs. Prior to joining DisperSol/Austhera, from 2014-2020, Snyder was the CFO of Exicure, Inc. (Nasdaq: XCUR) a company developing nucleic acid therapeutics. From 2008 to 2014, he was the CFO of Cellular Dynamics, Inc. (Nasdaq: ICEL) a company developing ipsc-based stem cell tools and primary cell therapeutics. From 2007-2008, Mr. Snyder served as Senior Vice President of Finance, Site Vice President and Chief Financial Officer of Roche NimbleGen. Prior to 2007, Snyder was CFO of companies in real estate, software, and manufacturing. Early in his career, Mr. Snyder worked for financial and real estate investor Sam Zell. He received his BA summa cum laude from Ottawa University and his M.B.A. with high honors from the Harvard Business School, where he was designated a George Fisher Baker Scholar.